Treatment of Schizophrenia with ergot derivatives

Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.